BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Clinical Development Path for Next-Gen Cancer Therapy

VERAXA Biotech (NASDAQ: VRXA) recently received favorable Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) regarding the development strategy for its lead BiTAC-TCE cancer therapy, providing regulatory guidance on the program’s biological rationale, pharmacokinetics and planned non-clinical safety studies ahead of potential clinical trials. The company views the feedback as an early regulatory validation that could reduce development uncertainty and clarify the path toward the clinic. VERAXA’s lead candidate previously produced encouraging preclinical results presented at the 2026 AACR Annual Meeting, where the company reported selective targeting of cancer cells carrying two biomarkers while sparing cells with only one, potentially improving the therapeutic window of conventional T-cell engagers. The company is now focused on completing non-clinical studies, advancing manufacturing and preparing for future regulatory submissions, while continuing to develop a broader oncology pipeline spanning bispecific T-cell engagers, ADCs and other engineered antibody therapies.

To view the full article, visit https://ibn.fm/U4ON1

About VERAXA Biotech AG

VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology. For regular updates about VERAXA Biotech, visit www.VERAXA.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN